Skip to main content
LNTH logo

Lantheus Holdings, Inc. (LNTH) Stock: Price, Forecast & Analyst Target

Lantheus Holdings, Inc. (LNTH) — MoonshotScore 96/100 (Exceptional band), calculated Nov 18, 2026. Price $102.10 (0.00%), as of the Nov 20, 2026 trading session; market cap $6.68B. Expected results Feb 25, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$102.10 $0.00 (0.00%) Market Cap $6.68B

Lantheus Holdings, Inc. · LNTH · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Research dated 2026-09-13: Lantheus supplies the specialized imaging agents that hospitals use to illuminate cancer cells and cardiac tissues during scans. The company transformed its financial profile by capturing the prostate cancer diagnostic market, leaving its valuation heavily dependent on extending that dominance while younger therapeutic candidates advance.

Price as of Nov 20, 2026

Key Statistics

96 of 100

MoonshotScore v2 · Lantheus Holdings (LNTH)

Exceptional
Business Quality Elite (90)
Financial Safety Fortress (97)
Valuation Fair (60)
Growth Durability Compounding (88)
Momentum Surging (90)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.

  • quarterly revenue $384M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 5.64 · Piotroski F 8

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LNTH (58 recorded, newest six shown)
RecordedScoreBand
94Exceptional
94Exceptional
94Exceptional
96Exceptional
96Exceptional
96Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$102.10
Change on the day0.00%
52-week range$51.84–$111.86
Market capitalisation$6.68B—
Price / earnings (trailing)24.59
Shares traded on the day1.07M
Beta (volatility vs the S&P 500)0.03

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $51, high $110, latest $102. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $110 $51 high $110 Feb 26, 2026 · Earnings results · reported above the recorded estimate · close $751May 7, 2026 · Earnings results · reported above the recorded estimate · close $932Aug 6, 2026 · Earnings results · reported above the recorded estimate · close $1013Nov 5, 2026 · Earnings results · reported above the recorded estimate · close $1014 Oct 17, 2025 Nov 20, 2026 · $102 $56Oct 17, 2025$58Oct 31, 2025$53Nov 14, 2025$59Nov 28, 2025$67Dec 12, 2025$67Dec 26, 2025$68Jan 9, 2026$68Jan 23, 2026$65Feb 6, 2026$74Feb 20, 2026$73Mar 6, 2026$76Mar 20, 2026$76Apr 2, 2026$84Apr 17, 2026$86May 1, 2026$94May 15, 2026$99May 29, 2026$105Jun 12, 2026$110Jun 26, 2026$106Jul 10, 2026$105Jul 24, 2026$101Aug 7, 2026$100Aug 21, 2026$101Sep 4, 2026$101Sep 18, 2026$100Oct 2, 2026$100Oct 16, 2026$100Oct 30, 2026$102Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Lantheus Holdings (LNTH): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Moderate
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Weak
Debt/Equity Neutral
ROE Strong
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Lantheus Holdings (LNTH), and what does it report?

Short answer · as of

Grouped with traditional generic drugmakers, Lantheus operates a fundamentally different model built on nuclear medicine and ultrasound contrast materials.

The company generates revenue by selling individual radioactive doses and microbubble injections that clinics administer right before running patient scans.

The bulk of the top line relies directly on an injectable agent that highlights prostate cancer cells on imaging equipment, supplemented by an established cardiac ultrasound product. Measuring this business means tracking specialized diagnostic procedure volumes rather than daily pharmacy prescriptions.

2 · Latest results

What do the latest results show for Lantheus Holdings (LNTH)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $384M.

Recent financial disclosures illustrate a stabilizing top line following an extended period of intense expansion, with recent sales missing analyst projections. Even as revenue growth cools, gross profitability remains exceptionally strong, reflecting the premium pricing power of specialized radiopharmaceuticals.

However, sustained research commitments continue to absorb a significant portion of operating income. The underlying mechanism is a maturing adoption curve for the flagship prostate cancer imaging agent, shifting the financial narrative from explosive market penetration toward steady cash generation.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$389.91M Nov 5, 2026
Latest report · revenue estimate
$355.74M Nov 5, 2026
Latest report · revenue vs estimate
Above estimate Nov 5, 2026
Latest report · EPS vs estimate
Above estimate Nov 5, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 5, 2026$389.91M$355.74M$1.6800$1.2300
Aug 6, 2026$388.18M$363.23M$1.5500$1.3000
May 7, 2026$377.33M$354.48M$1.4600$1.2500
Feb 26, 2026$406.79M$366.99M$1.6700$1.1800
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$384M$28M$0.41 (diluted)
Q4 FY2025$407M$54M$0.82 (diluted)
Q1 FY2026$377M$118M$1.80 (diluted)
Q2 FY2026$388M$75M$1.11 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Lantheus Holdings (LNTH)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow consistently outpaces capital requirements, providing the business with substantial liquidity to fund its clinical pipeline and strategic collaborations. The balance sheet supports this with manageable leverage and ample short-term investments that thoroughly cover immediate liabilities.

The acute risk lies in revenue concentration rather than solvency. Because the income statement depends heavily on a specific diagnostic agent, regulatory approval of competing prostate imaging tools or adjustments to clinical reimbursement rates would directly threaten the core profit engine.

4 · What to check next?

What should you watch next at Lantheus Holdings (LNTH)?

Short answer · as of

The next earnings report is expected on Feb 25, 2027.

The upcoming reporting cycle serves as a critical test of whether the company can reaccelerate its sales volume or if recent plateaus represent a structural ceiling for its current portfolio. Analysts have issued notable downgrades, signaling a market recalibration toward a more mature, slower-growth expectation.

Investors should monitor clinical updates regarding the radiopharmaceutical therapeutic pipeline, as advancing these specialized treatments remains the clearest path to diversifying revenue away from pure diagnostics.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The newest quarter held here (Q3 FY2025) was filed Nov 6, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Lantheus Holdings compare with its peers?

Short answer

Lantheus Holdings's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Unlike broad pharmaceutical peers that rely on recurring daily prescriptions for chronic care, Lantheus operates entirely within the episodic environment of the clinical imaging suite. Its core products involve radioactive isotopes that require complex manufacturing and highly synchronized distribution networks to accommodate rapid decay times.

This severe logistical complexity creates formidable barriers to entry, insulating margins more effectively than traditional patent cliffs. However, this same specialization strictly caps total addressable demand to the absolute volume of specific hospital scanning procedures performed.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Hinge Health, Inc. (HNGE) Named competitor$108.10 Nov 19, 2026$8.79B97 5-pillar Nov 18, 2026
Lantheus Holdings (LNTH) — this page$102.10$6.68B96
ANI Pharmaceuticals, Inc. (ANIP) Same industry, near in market value$68.55 Nov 20, 2026$1.56B94 5-pillar Nov 18, 2026
Pacira BioSciences, Inc. (PCRX) Same industry, near in market value$36.48 Nov 20, 2026$1.46B92 5-pillar Nov 18, 2026
Dr. Reddy's Laboratories Limited (RDY) Same industry, near in market value$14.89 Nov 20, 2026$12.4B77 5-pillar Nov 18, 2026
Supernus Pharmaceuticals, Inc. (SUPN) Same industry, near in market value$28.61 Nov 20, 2026$5.94B74 5-pillar Nov 18, 2026
HUTCHMED (China) Limited (HCM) Same industry, near in market value$13.22 Nov 20, 2026$2.30B70 5-pillar Nov 18, 2026
Amneal Pharmaceuticals, Inc. (AMRX) Named competitor$21.12 Nov 20, 2026$7.36B66 5-pillar Nov 18, 2026
Praxis Precision Medicines, Inc. (PRAX) Named competitor$300.43 Nov 20, 2026$8.40B60 5-pillar Nov 18, 2026
Regencell Bioscience Holdings Limited (RGC) Same industry, near in market value$4.36 Nov 19, 2026$2.16B47 5-pillar Nov 18, 2026
Elanco Animal Health Incorporated (ELAN) Same industry, near in market value$26.29 Nov 19, 2026$13.1B35 5-pillar Nov 18, 2026
Viatris Inc. (VTRS) Same industry, near in market value$19.63 Nov 20, 2026$22.5B35 5-pillar Nov 18, 2026
Bausch Health Companies Inc. (BHC) Same industry, near in market value$8.22 Nov 20, 2026$3.08B30 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$102.50 – $109.00
Consensus target
$104.38
Median target
$102.50

Consensus record · Captured .

Measured against a quoted price of $102.10 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 31, 2026

Transactions
3
Identified insiders
3
Purchases
0
Sales
0
Other transactions
3

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LNTH in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LNTH in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Lantheus Holdings (LNTH)?

Read these with our analysis →

LNTH Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

How does PYLARIFY contribute to the overall business?

The prostate cancer imaging agent acts as the primary financial engine, generating the absolute majority of total revenue. Its successful adoption transformed the company from a modest contrast provider into a highly profitable radiopharmaceutical leader.

What role does DEFINITY play in the product portfolio?

As a microbubble contrast agent for cardiac ultrasounds, this legacy product provides a steady, established income stream that complements the newer oncology diagnostics. It serves as a reliable secondary pillar that helps fund ongoing therapeutic research.

How do the logistical requirements of radioactive isotopes affect operations?

Materials like technetium and iodine possess incredibly brief shelf lives, requiring immediate dispatch from manufacturing sites directly to medical centers. This rapid decay mandates a flawless distribution network, which adds significant operational expense but simultaneously limits external competition.

Why are analysts adjusting their ratings on the stock?

Recent downgrades reflect concerns that the period of rapid expansion for the flagship diagnostic tool has concluded. Firms are realigning their models to account for a stabilizing sales environment and increasing competition in the specialized imaging space.

What is the LNTH stock price today?

The last price recorded for Lantheus Holdings, Inc. (LNTH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the LNTH price target?

The analyst consensus price target for Lantheus Holdings, Inc. (LNTH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 43 figures on this page — 38 from Financial Modeling Prep (FMP), 2 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • 1. What is Lantheus Holdings (LNTH), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Lantheus Holdings (LNTH)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Revenue by segment
  • 3. What are the financial strengths and risks for Lantheus Holdings (LNTH)?: Cash, investments and debt; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Revenue by segment
  • 4. What should you watch next at Lantheus Holdings (LNTH)?: Next earnings report; Analyst actions, most recent per firm; Business description; Analyst revenue and earnings estimates (average)
  • 5. How does Lantheus Holdings compare with its peers?: Business description; Sector / industry (provider taxonomy); Trailing twelve-month ratio set
  • FAQ: How does PYLARIFY contribute to the overall business?: Revenue by segment; Business description; Annual revenue and net result (USD millions)
  • FAQ: What role does DEFINITY play in the product portfolio?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: How do the logistical requirements of radioactive isotopes affect operations?: Business description; Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions)
  • FAQ: Why are analysts adjusting their ratings on the stock?: Analyst actions, most recent per firm; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold LNTH

Funds in our ETF coverage that list LNTH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
IVSS ETF1.24%